The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for ...
A seismic shift in pediatric medical care has arrived with the FDA’s approval of Ryoncil (remestemcel-L-rknd), a ...
The Australian sharemarket has extended a late end of year rally, sidestepping a tech selloff in the US overnight as volumes ...
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
Email Alerts for: Current price: $2.63 Market cap: $3.93bn Current price: $3.01 Current price: $2.31 Current price: $3.69 ...
Regenerative medicine company Mesoblast Ltd. received an early Christmas present from the FDA for approval of its allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, Ryoncil ...
US FDA approves Mesoblast’s mesenchymal stromal cell therapy, Ryoncil for steroid-refractory aGvHD in children 2 months and older: Melbourne, Australia Monday, December 23, 2024 ...
GEN presents data compiled by Morningstar's Morningstar Direct asset management platform for StockWatch of the top five ...
Meanwhile, synthetic gel aids in recovery after spinal surgery; Pittsburgh researchers create helper robots for people with ALS; a study finds nerve stimulation is effective against ...
The local bourse hit a three-month low on Friday as CBA led banks down, Mesoblast gave back some of its gains and the ASX had ...
The FDA has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute GVHD in pediatric patients age 2 months and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback